Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Trial details
- Registry ID
- NCT06431776
- Drugs studied
- Molgramostim
TrialRedline tracks 4 clinical trials sponsored by Savara Inc.: 3 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).NCT06431776 | Molgramostim | Recruiting | 2027-06Estimated |
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NCT04544293 | Molgramostim, Molgramostim Open-label | Active not recruiting | 2023-11-30Actual |
| Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisNCT03482752 | Molgramostim | Terminated | 2021-01-14Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) InfectionNCT03421743 | Antimycobacterial regimen, Inhaled molgramostim | Completed | 2019-10-15Actual |
Names as written in the registry records.
Before: Jan 2027. After: Jun 2027.
Before: Not yet recruiting. After: Recruiting.